![Diane J. Kalina](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Diane J. Kalina
President at BioCatalyst Yorkton, Inc.
Profile
Ms. Diane J.
Kalina is a Managing Director at PDC Biotech GmbH and President & Director at BioCatalyst Yorkton, Inc. She is on the Board of Directors at BioCatalyst Yorkton, Inc.
Ms. Kalina was previously employed as Head-Marketing, Director-New Products & Licensing by GSK Products, Inc., Chief Financial Officer by Mexigold Corp., and President & Director by YM BioSciences, Inc. She also served on the board at Arius Research, Inc.
Diane J. Kalina active positions
Companies | Position | Start |
---|---|---|
BioCatalyst Yorkton, Inc. | President | 01/01/2005 |
Former positions of Diane J. Kalina
Companies | Position | End |
---|---|---|
Arius Research, Inc.
![]() Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Director/Board Member | 06/12/2007 |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | President | - |
GSK Products, Inc.
![]() GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Sales & Marketing | - |
PDC Biotech GmbH
![]() PDC Biotech GmbH BiotechnologyHealth Technology PDC Biotech GmbH operates as a biopharmaceutical company developing innovative therapeutics for the treatment of preterm labor and primary dysmenorrheal in women. The firm’s pipeline products include prostaglandin F2a (FP) receptor antagonists, PDC31 a synthetic octapeptide, which is designed to act as an allosteric modulator of the receptor for prostaglandin FP receptor. The company was founded by Patricia Griffin and Diane J. Kalina in May 2008 and is headquartered in Vienna, Austria. | Chief Executive Officer | - |
E3 LITHIUM LIMITED | Director of Finance/CFO | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
E3 LITHIUM LIMITED | Process Industries |
Private companies | 5 |
---|---|
Arius Research, Inc.
![]() Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Health Technology |
BioCatalyst Yorkton, Inc. | |
PDC Biotech GmbH
![]() PDC Biotech GmbH BiotechnologyHealth Technology PDC Biotech GmbH operates as a biopharmaceutical company developing innovative therapeutics for the treatment of preterm labor and primary dysmenorrheal in women. The firm’s pipeline products include prostaglandin F2a (FP) receptor antagonists, PDC31 a synthetic octapeptide, which is designed to act as an allosteric modulator of the receptor for prostaglandin FP receptor. The company was founded by Patricia Griffin and Diane J. Kalina in May 2008 and is headquartered in Vienna, Austria. | Health Technology |
GSK Products, Inc.
![]() GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Distribution Services |
YM BioSciences, Inc.
![]() YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Diane J. Kalina